|
MechanismIL-6RA antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date16 Oct 2024 |
100 Clinical Results associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
0 Patents (Medical) associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
100 Deals associated with Jinyu Bowo Runze Biotechnology Co., Ltd.
100 Translational Medicine associated with Jinyu Bowo Runze Biotechnology Co., Ltd.